

Richard D Baird

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/991404/publications.pdf>

Version: 2024-02-01

90
papers

6,606
citations

147801

31
h-index

85541

71
g-index

95
all docs

95
docs citations

95
times ranked

12665
citing authors

#	ARTICLE	IF	CITATIONS
1	Liquid biopsies come of age: towards implementation of circulating tumour DNA. <i>Nature Reviews Cancer</i> , 2017, 17, 223-238.	28.4	1,786
2	Enhanced detection of circulating tumor DNA by fragment size analysis. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	670
3	First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 4688-4695.	1.6	506
4	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2013, 14, 882-892.	10.7	497
5	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. <i>Cell</i> , 2016, 167, 260-274.e22.	28.9	376
6	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan-Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 77-86.	7.0	265
7	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 423-433.	1.6	240
8	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 627-642.	27.6	230
9	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	10.7	196
10	Imaging breast cancer using hyperpolarized carbon-13 MRI. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2092-2098.	7.1	138
11	Drug resistance reversal—are we getting closer?. <i>European Journal of Cancer</i> , 2003, 39, 2450-2461.	2.8	127
12	Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK. <i>Clinical Cancer Research</i> , 2015, 21, 739-748.	7.0	121
13	Weekly paclitaxel in the treatment of recurrent ovarian cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 575-582.	27.6	95
14	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 4262-4272.	7.0	92
15	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. <i>Genome Medicine</i> , 2019, 11, 1.	8.2	84
16	A First-in-Human Study of the New Oral Selective Estrogen Receptor Degradar AZD9496 for ER+/HER2- Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3510-3518.	7.0	80
17	Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). <i>Annals of Oncology</i> , 2019, 30, 766-773.	1.2	78
18	A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 1.	5.0	75

#	ARTICLE	IF	CITATIONS
19	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. <i>Clinical Cancer Research</i> , 2014, 20, 5672-5685.	7.0	66
20	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	30.7	56
21	Genomic profile of advanced breast cancer in circulating tumour DNA. <i>Nature Communications</i> , 2021, 12, 2423.	12.8	54
22	AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1007-1007.	1.6	51
23	Genetic heterogeneity in breast cancer: the road to personalized medicine?. <i>BMC Medicine</i> , 2013, 11, 151.	5.5	47
24	Spontaneous remission of low-grade B-cell non-Hodgkin's lymphoma following withdrawal of methotrexate in a patient with rheumatoid arthritis: case report and review of the literature. <i>British Journal of Haematology</i> , 2002, 118, 567-568.	2.5	44
25	Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5860-5872.	7.0	44
26	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	13.2	44
27	Clinical Development of Novel Drug-Radiotherapy Combinations. <i>Clinical Cancer Research</i> , 2019, 25, 1455-1461.	7.0	42
28	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA. <i>Genome Research</i> , 2022, 32, 215-227.	5.5	41
29	Hyperpolarized ¹³ C MRI of Tumor Metabolism Demonstrates Early Metabolic Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Radiology Imaging Cancer</i> , 2020, 2, e200017.	1.6	40
30	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1430-1437.	4.1	39
31	Metabolic Imaging Detects Resistance to PI3K Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. <i>Cancer Cell</i> , 2020, 38, 516-533.e9.	16.8	38
32	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5188-5196.	7.0	29
33	A Bayesian adaptive design for biomarker trials with linked treatments. <i>British Journal of Cancer</i> , 2015, 113, 699-705.	6.4	26
34	Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3037-3037.	1.6	23
35	A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3021-3021.	1.6	21
36	First-in-Human Phase I Study of MP0250, a First-in-Class DARPIn Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2021, 39, 145-154.	1.6	20

#	ARTICLE	IF	CITATIONS
37	Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. <i>Nature Communications</i> , 2022, 13, .	12.8	19
38	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 6598-6605.	7.0	17
39	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1412-1424.	4.1	16
40	Final results of a translational phase I study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers.. <i>Journal of Clinical Oncology</i> , 2011, 29, 3001-3001.	1.6	16
41	RADICAL trial: A phase Ib/IIa study to assess the safety and efficacy of AZD4547 in combination with either anastrozole or letrozole in ER positive breast cancer patients progressing on these aromatase inhibitors (AIs).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1059-1059.	1.6	14
42	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. <i>British Journal of Cancer</i> , 2011, 104, 43-50.	6.4	12
43	A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3K β , in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2257-2269.	7.0	11
44	Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours. <i>European Journal of Cancer</i> , 2015, 51, 137-145.	2.8	9
45	An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. <i>European Journal of Cancer</i> , 2018, 103, 17-23.	2.8	8
46	Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). , 2020, , .		8
47	Serial monitoring of genomic alterations in circulating tumor cells of ER α -positive/HER2 α -negative advanced breast cancer: feasibility of precision oncology biomarker detection. <i>Molecular Oncology</i> , 2022, 16, 1969-1985.	4.6	8
48	First-in-class phase I study evaluating MPO250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2520-2520.	1.6	7
49	Thalidomide is Highly Effective in a Patient with Meningeal Acute Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 2004, 45, 179-181.	1.3	6
50	POSEIDON trial phase 1b results: Safety and preliminary efficacy of the isoform selective PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor (HR) positive, HER2-negative metastatic breast cancer (MBC) patients (pts) - including response monitoring by plasma circulating tumor (ct) DNA.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2520-2520.	1.6	6
51	Cambridge Brain Mets Trial 1 (CamBMT1): A proof of principle study of afatinib penetration into cerebral metastases (mets) for patients (pts) undergoing neurosurgical resection, combined with low-dose, targeted radiotherapy (RT)â€”Phase 1b results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2008-2008.	1.6	6
52	An Association of Cancer Physiciansâ€™ strategy for improving services and outcomes for cancer patients. <i>Ecanermedicalscience</i> , 2016, 10, 608.	1.1	5
53	Abstract OT1-03-02: MPO274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MPO274 in patients with advanced HER2-positive solid tumors. <i>Cancer Research</i> , 2018, 78, OT1-03-02-OT1-03-02.	0.9	5
54	A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3100-3100.	1.6	5

#	ARTICLE	IF	CITATIONS
55	Utilization of volumetric magnetic resonance imaging for baseline and surveillance imaging in Neuro-oncology. <i>British Journal of Radiology</i> , 2019, 92, 20190059.	2.2	4
56	Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2511-2511.	1.6	4
57	Abstract P1-19-17: Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer. <i>Cancer Research</i> , 2020, 80, P1-19-17-P1-19-17.	0.9	4
58	1248 POSTER A Phase I Study Evaluating GDC-0941, a Pan-phosphoinositide-3 Kinase (PI3K) Inhibitor, in Patients (pts) With Advanced Solid Tumours, Multiple Myeloma, and PIK3Ca Mutant (mt) Tumours. <i>European Journal of Cancer</i> , 2011, 47, S159.	2.8	3
59	Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications. <i>Clinical Oncology</i> , 2016, 28, 1-3.	1.4	3
60	Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2555-2555.	1.6	3
61	Carcinoma-induced diffuse pulmonary haemorrhage. <i>British Journal of Hospital Medicine</i> , 2002, 63, 176-177.	0.2	2
62	A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1185-1197.	2.3	2
63	The Consequences for Cancer Care and Cancer Research of Brexit. <i>Ecancermedicalsecience</i> , 2017, 11, ed63.	1.1	2
64	Abstract P4-12-24: Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer. <i>Cancer Research</i> , 2013, 73, P4-12-24-P4-12-24.	0.9	2
65	Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.. <i>Journal of Clinical Oncology</i> , 2010, 28, 2519-2519.	1.6	2
66	A pharmacodynamic biomarker study of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (CANCAPO2).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5081-5081.	1.6	2
67	Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment. , 2017, , .		2
68	A Road Map for Designing Phase I Clinical Trials of Radiotherapyâ€™Novel Agent Combinations. <i>Clinical Cancer Research</i> , 2022, 28, 3639-3651.	7.0	2
69	<i>Pneumocystis jiroveci</i> pneumonia (PCP) in patients receiving weekly chemotherapy for metastatic breast cancer. <i>Annals of Oncology</i> , 2017, 28, v98.	1.2	1
70	Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases. , 2016, , .		1
71	Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial. , 2020, , .		1
72	Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with aHER2mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		1

#	ARTICLE	IF	CITATIONS
73	Basket of baskets (BoB): A modular, open label, phase II, multicenter study to evaluate targeted agents in molecularly selected populations with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS3151-TPS3151.	1.6	1
74	A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity.. Journal of Clinical Oncology, 2011, 29, 3024-3024.	1.6	1
75	Antiapoptotic Effect of Growth Factors in Leukemia. Journal of Clinical Oncology, 2005, 23, 649-649.	1.6	0
76	Audit of epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) using Dako and Ventana clones in non-small cell lung cancer (NSCLC). Lung Cancer, 2009, 63, S2-S3.	2.0	0
77	362 First in human trial of a poly(ADP-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers. European Journal of Cancer, Supplement, 2010, 8, 114-115.	2.2	0
78	603 Baseline circulating tumor cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) Prognostic Score and improve patient selection for phase 1 clinical trials. European Journal of Cancer, Supplement, 2010, 8, 189-190.	2.2	0
79	Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF-A, in patients with advanced solid tumors. European Journal of Cancer, 2016, 69, S133.	2.8	0
80	CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. Annals of Oncology, 2016, 27, vi132.	1.2	0
81	Circulating tumour DNA analysis using three next generation sequencing approaches in a phase 1b trial of ER positive metastatic breast cancer. European Journal of Cancer, 2020, 138, S19.	2.8	0
82	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
83	Hereditary and Sporadic Cancers Respond to Niraparib. Cancer Discovery, 2013, 3, OF8-OF8.	9.4	0
84	CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.. Journal of Clinical Oncology, 2016, 34, 11530-11530.	1.6	0
85	CANCAPO2: A study into the pharmacodynamic biomarker effects of vistusertib (AZD2014), an mTORC1/2 inhibitor, given prior to radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 97-97.	1.6	0
86	Abstract OT1-04-01: Cambridge brain mets trial 1 (CamBMT1): A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. , 2017, , .		0
87	Abstract OT1-01-07: PIONEER- Pre-operative window study of letrozole plus PR agonist megestrol acetate versus letrozole alone in post-menopausal patients with ER-positive breast cancer. , 2019, , .		0
88	Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with an AKT1 mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		0
89	Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010). , 2020, , .		0
90	Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010). , 2020, , .		0